FDA News
🇪🇺 EMAEMA news and analysis for pharmaceutical BD, investment, and market access
Track critical FDA approvals, regulatory updates, and policy shifts impacting drug development and market access in the US. Stay ahead of compliance.
Showing 1–12 of 53 articles
Quick answer
NovaPharmaNews FDA News hub for EMA covers 53 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
FDA approves capivasertib plus abiraterone and prednisone in PTEN-deficient mHSPC
Truqap gains US approval in PTEN-deficient metastatic prostate cancer
AI in Drug Discovery Examples: What’s Changed Beyond Early Use Cases
Eye drugs list: Sodium hyaluronate, tafluprost, tobramycin uses
Federal Court Litigation on Reproductive Health: Rare Disease Implications
Regulatory round-up: 2 February 2026 – EMA opinions, FDA approvals, and what they mean for pharma
FDA Voucher Program Pause Urged: Rare Disease Policy Analysis
India-Oman CEPA Fast-Tracks Drug Approvals, Cuts Export Barriers for Pharma
Hayes Receives 2026 ESMO Breast Cancer Award: Key Insights
Owkin and AstraZeneca Enhance AI Collaboration for Drug Research
Insights from ESMO Asia: Nadia Harbeck on Oncology Advances
WHO/Europe Initiative on Access to Novel Medicines: Market Implications for Pharma
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.